| abstract |
A pharmaceutical composition for use in treating a disease selected from the group consisting of venous occlusion, diabetic retinopathy, macular degeneration and chronic retinal detachment, comprising a pharmaceutically acceptable carrier and an isolated monoclonal antibody that binds to the protein tyrosine human beta phosphatase (HPTPβ), wherein the isolated monoclonal antibody binds to the extracellular domain of HPTPβ, wherein the isolated monoclonal antibody is an intact monoclonal antibody produced by the hybridoma cell line ATCC No. PTA-7580, or a humanized form of the same. |